Skip to main content
Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A. — Investor Relations & Filings

Ticker · NWRN ISIN · IT0004147952 LEI · 8156002F8C11F80A9740 SW Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2024-05-13 Earnings Release
Country IT Italy
Listing SW NWRN

About Newron Pharmaceuticals S.p.A.

https://www.newron.com/

Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.

Recent filings

Filing Released Lang Actions
EQS-Adhoc:   Newron veröffentlicht zusätzliche Daten, welche die Wirksamkeit von Evenamide in der Zulassungsstudie 008A bei Schizophrenie-Patienten mit geringer Therapieansprache belegen
Earnings Release Classification · 99% confidence The document is titled "Ad hoc-Mitteilung gemäss Art. 53 KR" (Ad hoc announcement according to Art. 53 KR) and explicitly states it is an "Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014" (Insider information according to Article 17 of Regulation (EU) No 596/2014). It details positive clinical trial results for the drug Evenamide regarding schizophrenia treatment. This type of immediate, material, non-public information release, especially concerning clinical data that could impact stock price, is typically classified as a general regulatory announcement or an earnings/material event disclosure. Since it is not a full Annual Report (10-K), a specific Earnings Release (ER) focusing only on key figures, or a specific legal/director filing, it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings) or potentially ER if it were a scheduled earnings report, but here it is an unscheduled 'Ad hoc' disclosure of material study results. Given the context of immediate disclosure of material, non-public information (insider information) that is not a standard periodic report, RNS is the most appropriate general regulatory fallback, although it strongly relates to the substance of an ER/IR. However, since it is an unscheduled, ad-hoc disclosure of study results, and not a formal Earnings Release (ER) which usually summarizes quarterly financials, RNS serves as the best fit for a mandatory, immediate regulatory disclosure of material non-financial/clinical news. Q2 2024
2024-05-13 German
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Regulatory Filings Classification · 99% confidence The document is a news release disseminated via EQS News, announcing positive top-line results from a Phase II/III clinical study (Study 008A) for the drug evenamide in schizophrenia patients. It provides key efficacy and safety data, quotes the CMO, and announces a conference call to discuss the results. This content—the initial announcement of financial/operational results (in this case, clinical trial results which drive future revenue/valuation)—fits the definition of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific announcement of key operational results (clinical trial success) rather than a comprehensive periodic report (like 10-K or IR), 'ER' is the most appropriate fit among the specific operational categories, as clinical trial results often drive investor sentiment similarly to earnings. Given the context of a biopharma company, clinical trial results announcements are often categorized alongside earnings releases. It is not a comprehensive report (10-K, IR), a presentation (IP), or just a notice of publication (RPA).
2024-04-30 English
EQS-News: Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevanten Phase II/III-Studie 008A mit Evenamide in Schizophrenie-Patienten
Earnings Release Classification · 100% confidence The document is a press release issued via EQS-News announcing positive topline results from a Phase II/III clinical study (Study 008A) for the drug Evenamide in schizophrenia patients. It details primary and secondary endpoints, safety profiles, and next steps (a subsequent Phase III study). It also announces an investor conference call for the same day. This content structure—announcing key clinical trial results and providing immediate financial/investor context (like a conference call announcement)—is characteristic of an Earnings Release (ER) or a specific type of corporate news release that summarizes performance/developments. Since it is a detailed announcement of study results, which often drives investor sentiment and is released around earnings periods or major milestones, it fits best under 'Earnings Release' (ER) as it communicates key performance indicators (clinical trial success) rather than being a full regulatory report (like 10-K or IR) or a general regulatory filing (RNS). It is not a transcript (CT), a management discussion (MDA), or a formal financial supplement (XLSX). Given the focus on clinical trial success, it is a major operational/financial update. Q2 2024
2024-04-30 German
EQS-Adhoc: Newron: Positive Topline-Ergebnisse der potenziell zulassungsrelevanten Phase-II/III-Studie 008A mit Evenamide in Schizophrenie-Patienten
Regulatory Filings Classification · 99% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' and explicitly states it is 'Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014'. It announces positive topline results from a Phase-II/III clinical study (Evenamide in Schizophrenia). This type of announcement, detailing significant, non-public, price-sensitive information (like clinical trial results) released immediately under EU market abuse regulation (MAR Article 17), is typically classified as a general regulatory announcement or a specific type of earnings/material event disclosure. Since it is not a full Annual Report (10-K), a formal Earnings Release (ER) focusing only on key figures, or a Call Transcript (CT), it fits best under the general regulatory/ad-hoc disclosure category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for mandatory, ad-hoc regulatory disclosures that aren't explicitly covered by other specific financial report types, although it strongly resembles an ER/MDA hybrid. However, because it is an 'Ad hoc-Mitteilung' (Ad hoc announcement) under Swiss/EU rules, RNS serves as the best fit for mandatory, non-periodic, material news releases not classified elsewhere.
2024-04-30 German
EQS-Adhoc: Newron vermeldet die Resultate der Generalversammlung 2024
AGM Information Classification · 99% confidence The document is titled 'Newron vermeldet die Resultate der Generalversammlung 2024' (Newron reports the results of the 2024 General Meeting). It explicitly mentions the 'Generalversammlung' (General Meeting) and reports the voting outcomes on the agenda items. This directly corresponds to the definition of AGM Results/Voting Declaration. The code AGM-R (AGM Information) is appropriate as it reports the results of the AGM, which is a key component of AGM documentation, although DVA (Declaration of Voting Results & Voting Rights Announcements) is also highly relevant. Given the context of reporting the results of the meeting itself, AGM-R is the primary fit, as it covers materials shared during the AGM, which includes the results announcement. The document is short and reports the outcome, fitting the scope of AGM-R.
2024-04-17 German
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Regulatory Filings Classification · 95% confidence The document is a news release disseminated via EQS-News, titled 'EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Study results'. It details scientific data and clinical development outlook presented at a conference (SIRS 2024). This type of announcement, which communicates key operational or scientific updates outside of mandatory periodic financial reports (like 10-K or IR), often falls under general regulatory news or press releases. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific announcement like a dividend (DIV) or management change (MANG), and it is a direct communication of company news, it best fits the general Regulatory Filings category (RNS) as a fallback for corporate news announcements that don't fit other specific categories, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is an announcement *about* presentations. Given the structure as a news wire release detailing scientific updates, RNS is the most appropriate general classification for non-standard corporate disclosures.
2024-04-08 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.